While increased PD-L1 expression on TAM dampens T-cell mediated immunity against HRS cells, it provides part of the rational for the therapeutic use of PD-1 blockade, a strategy of proven success in cHL due to the high dependency of HRS cells on the PD-1/PD-L1 axis (41). The gene discussed is CD274; the disease is classic Hodgkin lymphoma.